Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Current therapies and investigational drugs for peripheral arterial disease.
Jun-ichi Suzuki,Munehisa Shimamura,Hiroyuki Suda,Kouji Wakayama,Hidetoshi Kumagai,Yuichi Ikeda,Hiroshi Akazawa,Mitsuaki Isobe,Issei Komuro,Ryuichi Morishita +9 more
TL;DR: Current treatments and investigational drugs of PAD are summarized and HGF is the most promising factor because it can induce angiogenesis without the induction of vascular inflammation and increased permeability.
Journal ArticleDOI
A possible new focus for stroke treatment – migrating stem cells
TL;DR: The role that exogenous stem cell transplantation may serve in facilitating the migration of endogenous stem cells to the site of injury is proposed, an idea termed ‘biobridge’.
Journal ArticleDOI
Emerging genomic applications in coronary artery disease.
Samir Damani,Eric J. Topol +1 more
TL;DR: Loss-of-function variants in the hepatic cytochrome 2C19 system have now been found to be the predominant genetic mediators of clopidogrel antiplatelet response, with variant carriers having a >3-fold increase in risk for stent thrombosis.
Journal ArticleDOI
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
Tiziano Barbui,Alessandro M. Vannucchi,Alessandra Carobbio,Elisa Rumi,Guido Finazzi,Heinz Gisslinger,Marco Ruggeri,Maria Luigia Randi,Mario Cazzola,Alessandro Rambaldi,Bettina Gisslinger,Lisa Pieri,Juergen Thiele,Animesh Pardanani,Ayalew Tefferi +14 more
TL;DR: Critically analyzed multiple variables predicting thrombosis in an inception multicenter cohort of 604 strictly WHO-defined PV patients conventionally considered at low-risk of thROMbosis to recognized subgroups at different incidence of thromBosis to propose more appropriate treatments.
Journal ArticleDOI
Diabetes and antiplatelet therapy: from bench to bedside.
TL;DR: Currently available antiplatelet agents are reviewed and an update on the advances and drawbacks of these agents used for secondary prevention in DM patients experiencing an ACS or undergoing PCI is delivered.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.